Media Coverage

Amniox Medical, Inc. Helping Serve Unmet Patient Needs and Allowing Wound Care Specialists to Improve Their Patients’ Outcomes

Amniox is currently focusing its research efforts on clinical trials to show an investigational form of their umbilical cord product can potentially help patients with chronic, complex wounds.

Amniox Medical Announces Results of Pilot Study using CLARIX® FLO for Relief of Moderate to Severe Pain Associated with Knee Osteoarthritis.

Amniox Medical, Inc. (Amniox), a TissueTech, Inc. company and pioneer in the clinical application of human birth tissue-based products, announced today the results from a single-center, prospective, investigator-initiated pilot study titled “Injectable Amniotic Membrane/Umbilical Cord Particulate for Knee Osteoarthritis.”

TissueTech Strengthens Senior Management Team with the Appointment of Vice President of Reimbursement and Government Affairs

Tim provides strategic oversight of reimbursement strategies for TissueTech’s future biologics pipeline of human cell and tissue-based products for use in regenerative medicine and oversees all reimbursement analyses activities….

Wound Healing Facilitated by Birth Tissue Products

Build a better regenerative medicine app, says TissueTech, and stem cells and their progeny will beat a path to its decellularized matrix…

Ventures Roundup: After $82M round, TissueTech looks to expand in Miami

The next five years will bring job growth and possible clinical advances for Miami-based TissueTech, which landed South Florida’s top venture capital deal during the second quarter…

Therapies and Products | Amniox

AMNIOX Medical’s products, containing human umbilical cord and amniotic membrane, can help orchestrate healing of the soft tissues, bones, nerves and cartilage while helping to manage functional recovery. Image courtesy of AMNIOX Medical Inc.

Tyler Richardson, director of marketing, Surgical Biologics, at AMNIOX Medical Inc., a subsidiary of TissueTech Inc., shared his insights on the market for the story. His full input is provided in the following Q&A…